Nicotinamide N-methyltransferase mRNA (NNMT mRNA)

Nicotinamide N-methyltransferase (NNMT) mRNA is the genetic template for the NNMT enzyme, which plays a pivotal role in cellular energy homeostasis and the regulation of methyl donor availability (UniProt P40261). The encoded enzyme catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH) (PubMed: 24722442). Research indicates that NNMT mRNA is significantly upregulated in the adipose tissue and livers of individuals with obesity and type 2 diabetes, contributing to metabolic dysfunction (Nature Medicine, 2015). Furthermore, NNMT is frequently overexpressed in various cancers, including gastric and colorectal carcinomas, where it supports tumor progression by modulating the epigenetic state of the cell (PubMed: 30104604). Targeting the mRNA directly using antisense oligonucleotides (ASOs) or RNA interference (RNAi) provides a method to downregulate the enzyme's activity, which has shown promise in preclinical models for reducing adiposity and improving glucose tolerance. One notable drug candidate, IONIS-NNMT-LRx, is an antisense oligonucleotide designed to specifically bind and promote the degradation of NNMT mRNA (Ionis Pharmaceuticals). By reducing NNMT expression, these therapies aim to preserve SAM and NAD+ levels, thereby addressing the underlying metabolic imbalances associated with chronic diseases. This target represents a novel approach in metabolic and oncological pharmacology, focusing on the intersection of metabolism and gene expression.

Other names

NNMT transcriptNicotinamide N-methyltransferase messenger RNANicotinamide N-methyltransferase mRNA

Antisense oligonucleotide-mediated degradation of mRNA via RNase H recruitment, leading to reduced protein translation.